Page last updated: 2024-11-04

risedronic acid and Pulmonary Fibrosis

risedronic acid has been researched along with Pulmonary Fibrosis in 1 studies

Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.

Pulmonary Fibrosis: A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.

Research Excerpts

ExcerptRelevanceReference
" We report a case of BRONJ in a patient following six years of oral BP administration for the management of osteoporosis, complicated by four years of prednisone therapy for pulmonary fibrosis."3.81Risk Factors in the Development of Oral Bisphosphonate-induced Osteonecrosis. ( Reiss, S; Sultan, D, 2015)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Reiss, S1
Sultan, D1

Other Studies

1 other study available for risedronic acid and Pulmonary Fibrosis

ArticleYear
Risk Factors in the Development of Oral Bisphosphonate-induced Osteonecrosis.
    The New York state dental journal, 2015, Volume: 81, Issue:6

    Topics: Abscess; Administration, Oral; Aged, 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw

2015